Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
|ClinicalTrials.gov Identifier: NCT01553175|
Recruitment Status : Completed
First Posted : March 14, 2012
Last Update Posted : July 14, 2016
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.
|Condition or disease||Intervention/treatment|
|Brain and Central Nervous System Tumors Kidney Cancer||Genetic: DNA analysis Genetic: gene expression analysis Genetic: mutation analysis Genetic: protein expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
- To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
- To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
- To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
- To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.
OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.
|Study Type :||Observational|
|Estimated Enrollment :||25 participants|
|Official Title:||Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors|
|Study Start Date :||March 2012|
|Primary Completion Date :||July 2016|
- Absence or presence BRG1 and BRM expression in rhabdoid tumors
- Mechanism of suppression of BRG1 and BRM genes
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01553175
|Principal Investigator:||David Reisman, MD, PhD||University of Florida|